INICIO

Continuation of the Revista Mexicana de Cardiología

  • Home
  • Instructions for authors
    • Instructions for authors
    • Regulations for the publication of supplements
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • About Us
    • About the Journal            
    • Publisher Policies
    • Previous Titles
    • Editorial Management
  • Contact





2026, Number 3

Cardiovasc Metab Sci 2026; 37 (3)

Clopidogrel-associated small vessel vasculitis in acute coronary syndrome: a diagnostic and therapeutic challenge

Velásquez-Ospina, Juanita; Pamplona-Tobón, Jorge Alejandro; Mejía-Zapata, Natalia; Patiño-Giraldo, Santiago; Gaviria-Aguilar, María Clara

ABSTRACT

The treatment of acute coronary syndrome includes the use of acetylsalicylic acid and a P2Y12 inhibitor, with clopidogrel being the most commonly used agent in clinical practice. Fortunately, hypersensitivity reactions to clopidogrel are uncommon; however, when they occur, they are typically type I reactions mediated by IgE (e.g., urticaria, angioedema, and cutaneous rash). Type III hypersensitivity reactions, such as small vessel vasculitis, are exceedingly rare and pose a therapeutic challenge, particularly in the setting of acute coronary syndrome (ACS). This case report shows an uncommon presentation that should be considered in patients receiving antiplatelet therapy.
  FULL TEXT PDF   FLIPBOOK

Keywords

clopidogrel leukocytoclastic vasculitis small vessel vasculitis acute coronary syndrome




  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5
  • Characterization of clinical and anatomical profile of patients with anomalous...
    2026, Vol.37, Núm. 3
  • Mobile application to standardize and facilitate invasive hemodynamic...
    2026, Vol.37, Núm. 3
  • Clopidogrel-associated small vessel vasculitis in acute coronary syndrome: a...
    2026, Vol.37, Núm. 3
  • Should the battery of the implantable cardioverter defibrillator be changed or...
    2026, Vol.37, Núm. 3
  • Ibogaine. A new nightmare for cardiologists in tourist cities?
    2026, Vol.37, Núm. 3
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3


Cardiovascular and Metabolic Science Vol. 37, Num. 3, Julio-Septiembre 2026. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 http://www.medigraphic.com/cms ancam@ancam.org.mx https://www.medigraphic.com/cms/ E-mail: revmexcardiol@gmail.com Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-022717130200-102. ISSN impreso: 2683-2828, ISSN electrónico: 2954-3835. Otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 30 de septiembre de 2026.

 

2026     |     https://www.cardiovascularandmetabolicscience.org.mx/